BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Breidinger S, Simpson R, Mangin E, Woolf E. Determination of suvorexant in human plasma using 96-well liquid–liquid extraction and HPLC with tandem mass spectrometric detection. Journal of Chromatography B 2015;1002:254-9. [DOI: 10.1016/j.jchromb.2015.07.056] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
Number Citing Articles
1 Carson M, Kerrigan S. Quantification of suvorexant in urine using gas chromatography/mass spectrometry. Journal of Chromatography B 2017;1040:289-94. [DOI: 10.1016/j.jchromb.2016.10.042] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 2.2] [Reference Citation Analysis]
2 Waters B, Hara K, Ikematsu N, Takayama M, Matsusue A, Kashiwagi M, Kubo S. Tissue Distribution of Suvorexant in Three Forensic Autopsy Cases. Journal of Analytical Toxicology 2018;42:276-83. [DOI: 10.1093/jat/bkx110] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
3 Skillman B, Kerrigan S. Quantification of suvorexant in blood using liquid chromatography-quadrupole/time of flight (LC-Q/TOF) mass spectrometry. Journal of Chromatography B 2018;1091:87-95. [DOI: 10.1016/j.jchromb.2018.05.006] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
4 Sullinger S, Bryand K, Kerrigan S. Identification of Suvorexant in Urine Using Liquid Chromatography-Quadrupole/Time-of-Flight Mass Spectrometry (LC-Q/TOF-MS). J Anal Toxicol 2017;41:224-9. [PMID: 28035034 DOI: 10.1093/jat/bkw132] [Reference Citation Analysis]
5 Iqbal M, Ezzeldin E, Khalil NY, Al-Rashood ST, Al-Rashood KA. Simple and Highly Sensitive UPLC-ESI-MS/MS Assay for Rapid Determination of Suvorexant in Plasma. J Anal Toxicol 2017;41:114-20. [PMID: 28376227 DOI: 10.1093/jat/bkw111] [Reference Citation Analysis]
6 Rajana N, Devi DR, Kumar Reddy DN, Babu JM, Basavaiah K, Balakumaran K. Characterization of Five Oxidative Degradation Impurities and One Process Impurity of Suvorexant Drug Substance by LC-MS/MS, HR-MS and 1D, 2D NMR: Validation of Suvorexant Drug Substance and Process Impurities by HPLC and UPLC. J Chromatogr Sci 2020;58:433-44. [PMID: 32134104 DOI: 10.1093/chromsci/bmaa003] [Reference Citation Analysis]
7 Iqbal M, Khalil NY, Ezzeldin E, Al-Rashood KA. Simultaneous Detection and Quantification of Three Novel Prescription Drugs of Abuse (Suvorexant, Lorcaserin and Brivaracetam) in Human Plasma by UPLC-MS-MS. J Anal Toxicol 2019;43:203-11. [PMID: 30295849 DOI: 10.1093/jat/bky078] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
8 Skillman B, Kerrigan S. CYP450-Mediated metabolism of suvorexant and investigation of metabolites in forensic case specimens. Forensic Sci Int 2020;312:110307. [PMID: 32473525 DOI: 10.1016/j.forsciint.2020.110307] [Reference Citation Analysis]
9 Iqbal M, Ezzeldin E, Khalil NY, Alam P, Al-rashood KA. UPLC-MS/MS determination of suvorexant in urine by a simplified dispersive liquid-liquid micro-extraction followed by ultrasound assisted back extraction from solidified floating organic droplets. Journal of Pharmaceutical and Biomedical Analysis 2019;164:1-8. [DOI: 10.1016/j.jpba.2018.10.005] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 3.7] [Reference Citation Analysis]
10 Skillman B, Kerrigan S. Identification of Suvorexant in Blood Using LC–MS-MS: Important Considerations for Matrix Effects and Quantitative Interferences in Targeted Assays. Journal of Analytical Toxicology 2020;44:245-55. [DOI: 10.1093/jat/bkz083] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
11 Bland H, Li X, Mangin E, Yee KL, Lines C, Herring WJ, Gillespie G. Effects of Bedtime Dosing With Suvorexant and Zolpidem on Balance and Psychomotor Performance in Healthy Elderly Participants During the Night and in the Morning. J Clin Psychopharmacol 2021;41:414-20. [PMID: 34181362 DOI: 10.1097/JCP.0000000000001439] [Reference Citation Analysis]